DRUG CHANNEL LANDSCAPE Q3 2022
The drug channel faces major headwinds as shoppers shift to value channels amid inflation to save money. Waning COVID-19 concerns are another drag on channel performance since retailers saw a sales boost when new variants emerged and at-home tests became available.
This IRI report looks at key emerging trends for the channel and shares recommendations for drug retailers on how to attract and keep customers in this challenging landscape.
How can we help you supercharge growth and profitability?
95% of CPG, retail, and health and beauty companies in the Fortune 100 work with us.
Copyright 2022 IRI. All Rights Reserved.